Last edition
News about "narcolepsy type 1"
Takeda's Oveporexton Improves Daily Function in Narcolepsy Type 1
Takeda’s phase 3 data show oveporexton improved daily function, cognition, and nighttime sleep in people with narcolepsy type 1. The results support the potential of the first orexin agonist therapy, with regulatory submissions currently under review.
Narcolepsy Type 1 | 16/06/2026 | By News Bureau
Takeda's Oveporexton NDA Accepted by US FDA with Priority Review for Narcolepsy Type 1
FDA grants Priority Review to Takeda’s investigational orexin receptor agonist oveporexton (TAK-861) for narcolepsy type 1, with a PDUFA decision expected in Q3 this year.
Narcolepsy Type 1 | 11/02/2026 | By News Bureau | 175
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy